NCT00902265

Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)

Efficacy and Safety of Nocturin 0.1 mg Tablets in Treatment of Nocturia in Patients With Nocturnal Polyuria, Lower Urinary Tract Symptoms (LUTS) and Benign Prostate Syndrome (BPS).

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 138 (actual)
• Sponsor: Ferring Pharmaceuticals · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin (Nocturin®) 0.1 mg tablet focusing on number of nocturnal voids, ratio of night/24-h urine volume (%), duration of first undisturbed sleep period and quality of life.

Conditions

• Nocturia Associated With Nocturnal Polyuria

Interventions

Type	Name	Description
DRUG	desmopressin	desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks

Timeline

• Start date: 2009-02-01
• Primary completion: 2010-03-01
• Completion: 2010-03-01
• First posted: 2009-05-15
• Last updated: 2011-04-19
• Results posted: 2011-04-11

Locations

140 sites across 1 country: Germany